~ PF614 and PF614-MPAR Discussed in Satellite Symposium on Severe Pain ~
SAN DIEGO, CA / ACCESSWIRE / August 8, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (“Ensysce” or the “Company”), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, provides a summary of its successful symposium at the International Association for the Study of Pain (IASP) 2024 World Congress on Pain in Amsterdam, Netherlands. The Company’s symposium illustrated the current landscape of severe pain, including post-surgical and cancer pain treatment, and discussed potential innovative treatment options, noting the limited number of new therapeutic agents approved in the last ten years.
Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce Biosciences, moderated the symposium entitled: ‘Severe Pain: A New Chapter for Safer Analgesics’, which featured Dr. Lars Arendt-Nielsen, Professor of Aalberg University of Medicine, Denmark, and Dr. William Schmidt, Chief Medical Officer of Ensysce Biosciences.
To begin, Dr. Arendt-Nielsen discussed the pros and cons of using opioids and the influence of genetics on pain and treatment plans. Dr. Schmidt reviewed the current options for treating pain, including use of opioid products, and the ideal profile for a new therapeutic agent. He highlighted Ensysce’s Trypsin Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR®) agents in development and discussed the safety and effectiveness of PF614 and PF614-MPAR. Dr. Schmidt concluded with an overview of the expected clinical studies for each in the coming year and reviewed their current positioning for commercial success.
Dr. Lynn Kirkpatrick, CEO of Ensysce, commented, “The IASP World Congress on Pain is an excellent meeting where top world experts gather to discuss innovative methods to help patients suffering from pain. Our team was pleased to have the opportunity to present the clinical data on our TAAP and MPAR technology platforms which demonstrate a unique approach to protect against prescription opioid abuse and oral overdose. We received excellent feedback on both the symposium content and our clinical strategy.”
The IASP has a mission to deliver pain relief throughout the world. Please find more information at the IASP website: https://www.iasp-pain.org
About Ensysce Biosciences
Ensysce Biosciences is a clinical-stage company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin-Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce’s products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.
Forward-Looking Statements
Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as “may,” “intends,” “can,” “might,” “will,” “expect,” “plan,” “possible,” “believe” and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce’s management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce’s business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce’s product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce’s and its partners’ ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce’s most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available, free of charge, at the SEC’s website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.
Ensysce Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196
Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us
SOURCE: Ensysce Biosciences Inc.
View the original press release on accesswire.com
